Coya publishes ALS study in peer-reviewed Frontiers in Neurology

Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis ALS at 24 weeks and a consistent reduction in inflammation, oxidative stress, and enhanced Regulatory T cell Treg number and suppressive function in patients who were administered a combination of CTLA4-Ig Fusion Protein or CTLA4-Ig, and Low Dose Interleukin-2 LD IL-2 ; Prior to initiating treatment, patients were declining at an average rate of -1.1 points per month on the ALSFRS-R rating scale- At the end of 6 months of treatment, the mean rate of change on the ALSFRS-R was +0.04 points per month. Coya Therapeutics a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell function, announces the publication of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neurology.Disease progression remained relatively unchanged during the first 6 months of CTLA4-Ig/LD IL-2 treatment Dr. Stanley Appel, MD, Edwards Distinguished Endowed Chair for ALS and Director, Johnson Center for Cellular Therapeutics at Houston Methodist stated, “The ability of the combination therapy to halt clinical progression in ALS for 24 weeks provides an important proof of concept for the protective role of Tregs while simultaneously suppressing inflammation. What is most gratifying is the concomitant reduction of the lipid peroxide 4-HNE as well as inflammatory cytokines. This study provides the basis for a large-scale double-blind placebo-controlled trial to establish potential therapeutic efficacy for ALS patients.”